Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. PMID: 28399408
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. PMID: 27208063
CD276 Promotes Vasculogenic Mimicry Formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs Pathway. PMID: 33204103
CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. PMID: 31948091
The Role of CD276 in Cancers. PMID: 33842369
Prognostic Significance of CD276 in Non-small Cell Lung Cancer. PMID: 31737785
CD276 (B7-H3) Maintains Proliferation and Regulates Differentiation in Angiogenic Function in Late Endothelial Progenitor Cells. PMID: 30379377
Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling. PMID: 32642118
Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma. PMID: 31998416
B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. PMID: 32398947
B7-H3 in Cancer - Beyond Immune Regulation. PMID: 29860983
B7-H3/CD276: An Emerging Cancer Immunotherapy. PMID: 34349762
B7-H3 role in the immune landscape of cancer. PMID: 28695059
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. PMID: 32874188
PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma. PMID: 33431797
[Next generation of anti-immune checkpoints antibodies]. PMID: 31903901
Cellular-Based Selections Aid Yeast-Display Discovery of Genuine Cell-Binding Ligands: Targeting Oncology Vascular Biomarker CD276. PMID: 30620189
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. PMID: 30753824
CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma. PMID: 33708423
CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. PMID: 31075138
Prognostic value of immune checkpoint molecules in breast cancer. PMID: 32602545
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. PMID: 32341579
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. PMID: 30655315
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. PMID: 28258693
A risk assessment model of acute liver allograft rejection by genetic polymorphism of CD276. PMID: 31044564
B7H3 ameliorates LPS-induced acute lung injury via attenuation of neutrophil migration and infiltration. PMID: 27515382
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. PMID: 33945793
Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. PMID: 29996538
Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. PMID: 24892449
Potential Therapeutic Targets of B7 Family in Colorectal Cancer. PMID: 32477326
Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma. PMID: 31629137
MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). PMID: 32145124
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. PMID: 32685008
Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. PMID: 34052626
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target. PMID: 30035102
Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. PMID: 24389327
Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. PMID: 33845814
Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. PMID: 31285949
CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1. PMID: 34290311
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. PMID: 31466914
A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity. PMID: 33798549
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. PMID: 32967924
Olive flounder CD276 (B7-H3) a coinhibitory molecule for T cells: Responses during viral hemorrhagic septicemia virus (VHSV) stimulation. PMID: 29253650
Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. PMID: 30930997
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. PMID: 28685773
B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression. PMID: 31974361
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. PMID: 31611650
Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. PMID: 30452269
Research progress of B7-H3 in malignant tumors., PMID:40519928
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621
PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer., PMID:40497528
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment., PMID:40493887
B7-H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development., PMID:40490821
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition., PMID:40452017
Prognostic Value of B7-H3 and a Novel Scoring System in Localized Renal Cell Carcinoma., PMID:40428825
B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer., PMID:40425233
HIV status alters immune cell infiltration and activation profile in women with breast cancer., PMID:40393975
MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization., PMID:40379833
Identification of Hub Genes and Pathways in Preinfusion Chimeric Antigen Receptor (CAR) T-cell Products Associated With Cytokine Release Syndrome., PMID:40370902
A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma., PMID:40330698
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
PKM2 modulates chemotherapy sensitivity by regulating autophagy and predicts the prognosis and immunity in pancancer., PMID:40287473
High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomes., PMID:40269882
Prognostic Significance of B7H3 Expression in Solid Tumors: A Systematic Review and Meta-Analysis., PMID:40243697
Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity., PMID:40229277
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer., PMID:40221152
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature., PMID:40214484
Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?, PMID:40207575
Molecular Imaging of B7-H3-Targeting Bispecific T Cell-Engaging Antibody MGD009 in Glioblastoma Models., PMID:40183579
Potential value of B7-H3 in sepsis diagnosis and prognosis: A Mendelian randomization study., PMID:40177762
Targeting CD276: a promising strategy for CAR-NK cell immunotherapy in human oral tongue squamous cell carcinoma., PMID:40169956
Establishing a Prognostic Model Correlates to Inflammatory Response Pathways for Prostate Cancer via Multiomic Analysis of Lactylation-Related Genes., PMID:40161494
Novel blood-based proteomic signatures across multiple neurodegenerative diseases., PMID:40145305
Microglia-Derived Brain Macrophages Associate with Glioblastoma Stem Cells: A Potential Mechanism for Tumor Progression Revealed by AI-Assisted Analysis., PMID:40136662
Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy., PMID:40121824
Impact of Radiometal Chelates on In Vivo Visualization of Immune Checkpoint Protein Using Radiolabeled Affibody Molecules., PMID:40109742
[Expression level and application analysis of soluble costimulatory molecule B7-H3 in the serum of patients with colorectal cancer]., PMID:40107790
Involvement of the disulfidptosis-related immune checkpoint gene, CD276, in glioblastoma malignant phenotype and poor prognosis., PMID:40079417
Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4+ T cells in humans., PMID:40070836
B7-H3-mediated deubiquitination stabilizing CYP1B1 expression promotes chemotherapy resistance in colorectal cancer., PMID:40057208
Gene Expression Signatures of Porcine Bone Marrow-Derived Antigen-Presenting Cells Infected with Classical Swine Fever Virus., PMID:40006915
Identification of the B7-H3 Interaction Partners Using a Proximity Labeling Strategy., PMID:40004194
Histone lactylation-driven B7-H3 expression promotes tumor immune evasion., PMID:39990209
Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer., PMID:39988897
CD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study., PMID:39975728
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project., PMID:39938010
The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma., PMID:39928563
UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy., PMID:39915000
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer., PMID:39914189
Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity., PMID:39892447
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study., PMID:39863300
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells., PMID:39848690
Identification and characterization of CD83 and CD276 as markers of dendritic cells in olive flounder (Paralichthys olivaceus)., PMID:39848419
A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity., PMID:39847994
A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies., PMID:39847434
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets., PMID:39825754
An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy., PMID:39824298
Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics., PMID:39814321
For research use only. Not for human or drug use.
